Biotechnology

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

April 9, 2024 8:45 AM

Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve® PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024 IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Andrew...

Read more

Data4Cure Announces a Late-Breaking Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting

April 8, 2024 5:15 PM

WALTHAM, MA / ACCESSWIRE / April 8, 2024 / Data4Cure, a leading biomedical data-to-knowledge company, today announced a late-breaking research poster presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5 to April 10, 2024, in San Diego, California. Data4Cure researchers will demonstrate how the company's Biomedical Intelligence platform enables deep interrogation and actionable...

Read more

CARDIO inCode-Score Clinical Publication on Polygenic Risk of Coronary Heart Disease

April 5, 2024 9:00 AM

US Study Publication in the American Journal of Preventive Cardiology OXFORD, UK / ACCESSWIRE / April 5, 2024 / GENinCode Plc (www.genincode.com) the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces today the publication by the American Journal of Preventive Cardiology of a study on ‘Polygenic Risk and Incident Heart Disease in a large multiethnic cohort'1.. The Kaiser Permanente Division of...

Read more

Indica Labs and Molecular Instruments Announce Partnership to Advance AI-Powered Quantitative Image Analysis with HCR(TM) RNA-ISH

April 5, 2024 8:00 AM

ALBUQUERQUE, NM and LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / Indica Labs, a leading provider of AI-powered digital pathology solutions, and Molecular Instruments® (MI), the inventor of the HCR™ Imaging technology, announce a new partnership to co-market compatibility between MI's patented HCR™ Imaging technology and Indica's HALO® software. HCR™ RNA-ISH sets a new industry standard with its array of clinical-grade features including...

Read more

BioInvent International AB Publishes Annual Report 2023

April 4, 2024 7:55 AM

LUND, SWEDEN / ACCESSWIRE / April 4, 2024 / BioInvent International AB (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2023 has been published. The Annual Report is attached to this press release in pdf format and is available on the company's website,...

Read more

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

April 4, 2024 2:50 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / April 4, 2024 / Vicore Pharma Holding (STO:VICO) The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804 ("Vicore Pharma" or the "Company"), with its registered offices in Stockholm, are summoned to the annual general meeting on Tuesday 7 May 2024 at 14.00 in the premises of the law firm Vinge at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 13.45. Shareholders can...

Read more

Ondine Biomedical Inc. Announces Entry into ICU Market Expands Revenue Potential

April 4, 2024 2:00 AM

Following interest from Canadian Hospitals, Ondine prepares to enter the Intensive Care Unit (ICU) market Treatment of patients in ICUs would significantly expand Ondine's potential market opportunity. Hundreds of thousands of patients are admitted to the ICU every year in Canada alone, with an average stay of over four days. [1] One in every eight patients in Canadian ICUs develops an infection not related to their presenting medical illness....

Read more

Genflow Biosciences PLC Announces Successful Placing and Subscription

April 4, 2024 2:00 AM

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. MARKET SOUNDINGS WERE TAKEN IN...

Read more

Study Shows hTERT Vaccination Induces Immunological Responses and Prevents Progression in a Subset of Therapy-Resistant Poor Prognosis Cancer Patients

April 3, 2024 9:00 AM

WASHINGTON, DC / ACCESSWIRE / April 3, 2024 / In a significant stride towards active immune therapy of cancer, a recently featured article in Experimental Biology and Medicine (Volume 249, Issue 1) describes a Phase 1 clinical trial, led by James Spicer and colleagues at King's College London. Entitled "A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor...

Read more

Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

April 3, 2024 8:00 AM

Clairvoyant on target for potential commercialization of psilocybin treatment in 2025 VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company developing psilocybin treatment for alcohol use disorder (AUD), today announced that it is on target to potentially become the first in the world to commercialize clinically validated psilocybin treatment....

Read more

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

April 3, 2024 7:00 AM

TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway $31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025 TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represents...

Read more

The BWB Awards at Biotech Week Boston Return for a Celebratory Gala September 23rd, 2024

April 2, 2024 11:45 AM

BOSTON, MA / ACCESSWIRE / April 2, 2024 / The BWB Awards at Biotech Week Boston returns for a night of dinner, drinks, entertainment, and the recognition of the top individuals, companies, and organizations in the life sciences community. Since 2018, the Awards at the Biotech Week Boston festival have been bringing together the faces and names that make the Boston community the beating heart of the biotech world. Join 200+ leaders across the...

Read more

Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status

April 2, 2024 9:15 AM

Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant potential benefits of technology assistance in an OTC setting (Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 2, 2024 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a...

Read more

BioInvent Announces a New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1910, the Company’s Second Anti-TNFR2 Antibody in Combination with KEYTRUDA(R) (Pembrolizumab)

April 2, 2024 9:15 AM

Agreement covers Phase 1/2a trial with TNFR2 agonist antibody BI-1910 First data from BI-1910 single agent arm expected by YE 2024 LUND, SWEDEN / ACCESSWIRE / April 2, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces a clinical trial collaboration and...

Read more

Edesa Biotech to Participate in Upcoming Investor Conferences

April 2, 2024 9:00 AM

TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management plans to participate in the following upcoming investor conferences: Mintz Conference, Toronto, Canada, April 15, 2024 LSX World Congress, London, UK, April 29-30, 2024, with showcase presentation at 4:30 pm...

Read more

Repair Biotechnologies Demonstrates Rapid Reversal of Atherosclerosis in Mouse Models

April 2, 2024 9:00 AM

Following favorable FDA feedback for the treatment of liver disease, the company is preparing further pre-IND meetings with the FDA for the treatment of atherosclerosis and familial hypercholesterolemia SYRACUSE, NY / ACCESSWIRE / April 2, 2024 / Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com) announced today that its lipid nanoparticle (LNP)/messenger RNA (mRNA) therapy has rapidly reversed the progression of...

Read more

Genvor to Participate in BioAgTech World Congress in Raleigh, North Carolina

April 2, 2024 8:31 AM

CHAPEL HILL, NC / ACCESSWIRE / April 2, 2024 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a developer of sustainable plant health solutions leveraging patented peptides, today announced that management will attend the 5th BioAgTech World Congress taking place April 22-26, 2024 in Raleigh, North Carolina. The BioAgTech World Congress is produced 'by the BioAg industry and for the BioAg industry' with the objective of enabling...

Read more

XiltriX North America Elevates Its Commitment to Security With SOC 2 Type 2 for Its Monitoring-as-a-Service Offering

April 2, 2024 7:00 AM

SAN DIEGO, CA / ACCESSWIRE / April 2, 2024 / XiltriX North America, LLC, a leading provider of real-time environmental monitoring systems for the life science industry, is proud to announce it has received a clean Service Organization Control (SOC) 2 Type 2 attestation report. Developed by the American Institute of Certified Public Accounts (AICPA), SOC 2 is an extensive auditing procedure that ensures that a company is handling customer data...

Read more

Lumira Ventures Announces Investment in Nocion Therapeutics to Revolutionize Chronic Cough Treatment

April 2, 2024 7:00 AM

TORONTO, ON / ACCESSWIRE / April 2, 2024 / Lumira Ventures is delighted to announce its latest investment in Nocion Therapeutics, a clinical-stage biopharmaceutical company developing first and potentially best-in-class, small molecule charged sodium channel blockers (CSCBs), called Nocions. These innovative compounds are designed to selectively silence activated nociceptors for the treatment of serious conditions involving cough, itch, and...

Read more

Selux Diagnostics Announces Additional $48 Million in Funding

April 1, 2024 8:12 AM

This additional funding comes at the heels of Selux announcing their third FDA 510(k) clearance on their direct from Positive Blood Culture Separator, making them the only single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies. BOSTON, MA / ACCESSWIRE / April 1, 2024 / Selux Diagnostics, Inc., a Boston based Biotech startup whose mission is to combat superbug infections and fight...

Read more